# Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

> **NCT05053152** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NRG Oncology** · enrollment: 194 (estimated)

## Conditions studied

- Oligometastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Prostate Ductal Adenocarcinoma
- Prostate Intraductal Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **OTHER:** Fluciclovine F18
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Placebo Administration
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** PSMA PET Scan
- **DRUG:** Relugolix
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT05053152
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-20
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05053152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05053152, "Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05053152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*